[Hub]/) : Traits : Medication: Allopurinol :

chr4:9,370,814-11,156,010

Best TWAS P=2.84e-56 · Best GWAS P=4.18e-69 conditioned to NaN

Associated models

# Study Tissue Gene h2 eQTL R2 model # weights model R2 model R2 P eQTL GWAS Z TWAS Z TWAS P Top SNP corr PP3 PP4 joint
1 CommonMind Brain Pre-frontal Cortex WDR1 0.04 0.01 enet 10 0.03 3.8e-04 -11.5 5.9 3.3e-09 -0.02 0.27 0.02 FALSE
2 GTEx Adipose Subcutaneous SLC2A9 0.06 0.06 lasso 2 0.04 6.1e-04 -11.4 11.3 1.3e-29 -0.34 0.42 0.06 FALSE
3 GTEx Adipose Subcutaneous RP11-448G15.3 0.08 0.06 lasso 4 0.07 3.8e-06 6.5 5.8 4.8e-09 -0.37 0.69 0.02 TRUE
4 GTEx Adipose Visceral Omentum SLC2A9 0.15 0.02 lasso 4 0.04 3.6e-03 10.5 8.7 2.8e-18 -0.11 0.31 0.06 FALSE
5 GTEx Adipose Visceral Omentum RP11-448G15.3 0.10 0.02 lasso 6 0.03 9.6e-03 -17.1 15.8 2.8e-56 -0.61 0.10 0.17 TRUE
6 GTEx Adrenal Gland RP11-448G15.3 0.10 0.07 enet 10 0.05 9.2e-03 6.5 9.4 7.6e-21 -0.55 0.14 0.33 FALSE
7 GTEx Artery Aorta SLC2A9 0.06 0.08 enet 4 0.08 3.7e-05 5.6 6.0 2.1e-09 -0.39 0.86 0.01 FALSE
8 GTEx Artery Aorta RP11-448G15.3 0.11 0.10 lasso 4 0.07 6.6e-05 6.5 5.2 2.5e-07 -0.32 0.88 0.01 FALSE
9 GTEx Artery Coronary SLC2A9 0.11 0.11 enet 4 0.08 8.6e-04 4.6 7.9 2.6e-15 -0.30 0.42 0.06 FALSE
10 GTEx Artery Tibial WDR1 0.19 0.06 enet 26 0.10 1.6e-08 5.7 7.6 3.2e-14 -0.42 0.99 0.00 FALSE
11 GTEx Artery Tibial SLC2A9 0.25 0.29 lasso 6 0.27 4.2e-21 6.5 7.0 3.1e-12 -0.39 1.00 0.00 FALSE
12 GTEx Artery Tibial ZNF518B 0.06 0.07 lasso 4 0.04 2.2e-04 5.9 5.9 4.4e-09 -0.24 0.94 0.00 FALSE
13 GTEx Artery Tibial RP11-448G15.3 0.22 0.11 enet 25 0.16 8.7e-13 6.5 7.8 9.3e-15 -0.35 0.98 0.00 FALSE
14 GTEx Breast Mammary Tissue RP11-448G15.3 0.18 0.01 lasso 10 0.07 2.2e-04 -13.5 12.0 3.4e-33 -0.69 0.42 0.21 FALSE
15 GTEx Cells Transformed fibroblasts RP11-448G15.3 0.07 0.03 lasso 3 0.03 3.8e-03 5.7 6.4 1.2e-10 -0.32 0.75 0.01 FALSE
16 GTEx Colon Sigmoid SLC2A9 0.26 0.11 lasso 13 0.15 5.9e-06 4.6 6.5 1.1e-10 -0.30 0.68 0.04 FALSE
17 GTEx Colon Transverse SLC2A9 0.08 0.04 lasso 1 0.01 7.7e-02 5.9 5.9 3.9e-09 -0.35 0.19 0.04 TRUE
18 GTEx Colon Transverse RP11-448G15.3 0.12 0.00 lasso 6 0.00 6.5e-01 6.7 5.4 5.9e-08 -0.11 0.20 0.04 FALSE
19 GTEx Esophagus Mucosa RP11-448G15.3 0.07 0.01 enet 10 0.02 1.2e-02 -2.8 9.4 7.0e-21 -0.28 0.37 0.06 TRUE
20 GTEx Esophagus Muscularis SLC2A9 0.19 0.14 lasso 6 0.22 1.2e-13 4.8 7.3 2.0e-13 -0.33 1.00 0.00 FALSE
21 GTEx Esophagus Muscularis RP11-448G15.3 0.11 0.00 enet 14 0.03 1.1e-02 -3.1 8.7 4.4e-18 -0.32 0.25 0.06 FALSE
22 GTEx Liver SLC2A9 0.18 0.13 lasso 6 0.12 3.7e-04 5.8 7.4 1.5e-13 -0.01 0.34 0.04 TRUE
23 GTEx Nerve Tibial WDR1 0.12 0.02 lasso 5 0.03 1.8e-03 7.4 10.4 2.0e-25 -0.41 0.32 0.18 TRUE
24 GTEx Nerve Tibial RP11-448G15.3 0.22 0.10 enet 27 0.23 2.6e-16 6.5 9.7 2.0e-22 -0.38 1.00 0.00 FALSE
25 GTEx Skin Sun Exposed Lower leg SLC2A9 0.18 0.03 enet 15 0.06 1.2e-05 11.1 11.4 5.5e-30 -0.30 0.56 0.07 FALSE
26 GTEx Thyroid RP11-448G15.3 0.17 0.05 enet 40 0.12 1.3e-09 6.5 6.0 2.8e-09 -0.24 0.90 0.00 TRUE
27 GTEx Whole Blood SLC2A9 0.11 0.04 lasso 6 0.05 9.9e-06 4.9 6.0 1.8e-09 -0.37 0.92 0.00 FALSE
28 METSIM Adipose SLC2A9 0.05 0.04 lasso 4 0.03 9.3e-06 10.5 9.8 1.4e-22 -0.19 1.00 0.00 FALSE
29 ROSMAP Brain Pre-frontal Cortex RP11-448G15.3 0.06 0.04 blup 552 0.05 7.9e-07 6.5 10.9 6.9e-28 -0.55 0.96 0.04 TRUE
30 The Cancer Genome Atlas Breast Invasive Carcinoma WDR1 0.04 0.02 lasso 5 0.03 1.7e-06 -8.0 -5.8 8.6e-09 0.00 0.98 0.00 FALSE
31 The Cancer Genome Atlas Cervical Squamous Cell Carcinoma ZNF518B 0.08 0.04 lasso 2 0.01 1.2e-01 -6.5 -6.6 3.6e-11 0.22 0.02 0.11 FALSE
32 The Cancer Genome Atlas Esophageal Carcinoma SLC2A9 0.16 0.02 enet 20 0.05 1.4e-02 5.8 5.7 1.2e-08 -0.16 0.04 0.05 TRUE
33 The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma ZNF518B 0.09 0.01 enet 8 0.04 2.7e-05 -6.5 -6.2 5.2e-10 0.12 0.27 0.04 FALSE
34 The Cancer Genome Atlas Ovarian Serous Cystadenocarcinoma SLC2A9 0.11 0.06 lasso 2 0.05 3.9e-04 4.8 -5.3 1.2e-07 0.28 0.55 0.07 TRUE
35 The Cancer Genome Atlas Stomach Adenocarcinoma WDR1 0.06 0.03 blup 111 0.01 3.2e-02 5.5 -7.2 5.0e-13 0.30 0.02 0.57 FALSE